DALLAS / Nov 25, 2024 / Business Wire / Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will host an R&D Day on December 3, 2024 at 4:30 p.m. ET.
The R&D Day will focus on the development of FB102 across autoimmune indications and will feature key thought leaders in celiac disease, vitiligo and alopecia areata including Prof. Jason Tye-Din MD, PhD, Head of Celiac Research at the Walter and Eliza Hall Institute, Prof. Christopher Ma MD, MPH, FRCPC, academic gastroenterologist at the Cumming School of Medicine, University of Calgary and Prof. David Rosmarin, MD, Chair of the Department of Dermatology at the School of Medicine, Indiana University.
Use the link below to register for the event: https://lifescievents.com/event/fortebiorx/
About Forte
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.
| Last Trade: | US$21.50 |
| Daily Change: | 1.80 9.14 |
| Daily Volume: | 134,958 |
| Market Cap: | US$137.380M |
November 14, 2024 August 14, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
